Moderna reports first quarter 2023 financial results and provides business updates

First quarter 2023 revenues of $1.9 billion; gaap net income of $79 million and gaap diluted eps of $0.19 company in negotiations for new orders for fall of 2023 in u.s., japan, and eu, in addition to reiterating 2023 minimum sales expectations of approximately $5.0 billion from previously announced covid-19 vaccine advanced purchase agreements company preparing for potential 2024 commercial launch of its investigational rsv vaccine for older adults company to begin phase 3 trial this year of mrna-4157, moderna's individualized neoantigen therapy (int) in combination with keytruda®, for melanoma company preparing for six major vaccine launches from respiratory franchise (covid-19, rsv, flu, and combinations), with expected annual sales of $8-15 billion by 2027 cambridge, ma / accesswire / may 4, 2023 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today reported financial results and provided business updates for the first quarter of 2023. "we had a strong first quarter, with $1.9 billion in revenue, clearly indicating that we are on our way to deliver on the $5 billion of signed advance purchase agreements for 2023.
MRNA Ratings Summary
MRNA Quant Ranking